BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Stock Information for Oncotelic Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncotelic Therapeutics Inc

OTC Markets Group Announces Quarterly Index Performance and Rebalancing
BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.